Soleno Therapeutics Earnings Reports

Soleno Therapeutics reported a net loss of $76.6 million for the third quarter ended September 30, 2024. The FDA accepted the NDA for DCCR with a PDUFA target action date of December 27, 2024.

Soleno Therapeutics reported a net loss of $21.9 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $294.6 million as of June 30, 2024. Research and development expenses increased to $12.3 million, and general and administrative expenses rose to $10.9 million.

Soleno Therapeutics reported a net loss of $21.4 million for the quarter ended March 31, 2024. The company's research and development efforts are primarily focused on advancing its lead product candidate, DCCR, for the treatment of PWS. As of March 31, 2024, Soleno had $42.8 million of cash and cash equivalents, $106.8 million of short-term investments, and $8.8 million of long-term investments.

Soleno Therapeutics reported a net loss of $11.3 million for the fourth quarter of 2023. The company's research and development expenses were $8.7 million, and general and administrative expenses were $4.1 million. As of December 31, 2023, Soleno had cash and cash equivalents of approximately $169.7 million.

Soleno Therapeutics reported a net loss of $8.5 million for the second quarter of 2023. The company's research and development expenses were $5.1 million, and general and administrative expenses were $3.2 million. As of June 30, 2023, Soleno had cash and cash equivalents of approximately $19.4 million.

Soleno Therapeutics reported a net loss of $8.4 million for the first quarter of 2023. The company's research and development efforts are primarily focused on advancing its lead product candidate, DCCR, for the treatment of PWS.